Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of NNZ-2591 in Children and Adolescents With Pitt Hopkins Syndrome
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Neuren Pharmaceuticals Limited. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Neuren Pharmaceuticals Limited a question about this update.